FCMV
CGEM icon

Foresite Capital Management V’s Cullinan Oncology CGEM Stock Holding History

Foresite Capital Management V’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-657,905
Closed -$8.01M – 7
2024
Q4 		$8.01M Hold
657,905
– – 6.67% 5
2024
Q3 		$11M Hold
657,905
– – 7.65% 5
2024
Q2 		$11.5M Buy
+657,905
New +$14M 7.33% 5
2022
Q2 		– Sell
-992,507
Closed -$10.4M – 15
2022
Q1 		$10.4M Sell
992,507
-150,499
-13% -$2.03M 4.24% 8
2021
Q4 		$17.6M Sell
1,143,006
-1,588,404
-58% -$31.7M 4.33% 6
2021
Q3 		$61.6M Hold
2,731,410
– – 19.16% 2
2021
Q2 		$70.3M Hold
2,731,410
– – 27.67% 1
2021
Q1 		$114M Buy
+2,731,410
New +$111M 33.46% 1

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Foresite Capital Management V's CGEM Position: Q1 2025 in Review

Foresite Capital Management V sold out of Cullinan Oncology (CGEM) in Q1 2025, closing a stake of 657,905 shares — an estimated $8.01M sold.

Foresite Capital Management V first reported a position in CGEM in Q1 2021 and held it in 8 quarters. The position peaked at $114M in Q1 2021. 148 funds tracked by Wall St. Rank hold CGEM as of Q1 2025.

  • Foresite Capital Management V reported no remaining Cullinan Oncology position as of Q1 2025 after selling out during the quarter.
  • Foresite Capital Management V sold 657,905 Cullinan Oncology shares in Q1 2025, an estimated $8.01M.
  • Foresite Capital Management V first reported a position in Cullinan Oncology in Q1 2021 and held it in 8 quarters.
  • Foresite Capital Management V's Cullinan Oncology position peaked at $114M in Q1 2021.
  • 148 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2025.

Based on Foresite Capital Management V's 13F filing for Q1 2025, filed 15 May 2025.